5 news items
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
AUTL
31 May 24
CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
AUTL
17 May 24
is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
AUTL
2 Apr 24
Authorization Application (MAA) for obecabtagene autoleucel (obe-cel). Obe-cel is Autolus' lead investigational chimeric antigen receptor (CAR) T cell
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
AUTL
14 Mar 24
)Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
AUTL
12 Mar 24
. About obe-cel (AUTO1)Obe-cel is a CD19 CAR T cell investigational therapy designed
- Prev
- 1
- Next